Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generics Bulletin Originals

Set Alert for Originals
What's Next?

What’s Next? Five Things To Look Out For In June

Generics Bulletin previews the most notable and anticipated events for June 2023.

Biosimilars Generic Drugs

What’s Next? Five Things To Look Out For In May

Generics Bulletin previews the most notable and anticipated events for May 2023.

Generic Drugs Biosimilars

What’s Next? Five Things To Look Out For In April

Generics Bulletin previews the biggest events and changes for industry in the coming month.

Biosimilars Generic Drugs

What’s Next? Five Things To Look Out For In March

Prepare for all the biggest industry actions and events in March 2023 with Generics Bulletin’s monthly column.

Biosimilars Generic Drugs
See All
Interviews

UAE’s Bioventure Is Looking For Partners To Expand

Having recently added to its biosimilars alliance with Alvotech, Dubai-based Bioventure says it is looking to expand its international reach through further partnerships.

Strategy Deals

Global Harmonization Efforts Must Go Further

With global regulation of off-patent medicines continuing to evolve, IGBA secretary general Suzette Kox talks about the progress expected from regulatory harmonization for generics and a reduced clinical trial burden for biosimilars.

Regulation International

Accord EMENA Chief Says Industry Is Pushing Back On Pressures

Amid continuing cost inflation, downwards pressure on prices, industry shortages and other supply-chain disruptions, Paul Tredwell – Accord’s executive vice-president for the Europe, Middle East and North Africa region – talks about how the off-patent industry is seeking to improve its operating environment.

Regulation Pricing Strategies

Accord Sees Benefits From Unique Portfolio

With Accord boasting a broad portfolio that encompasses generics, biosimilars, hybrid medicines and specialty products, Paul Tredwell – the firm’s executive vice-president for the Europe, Middle East and North Africa region – explains how this gives the company a unique position in the market.

Strategy Generic Drugs
See All
Pricewatch UK

Ivabradine Prices Rise High Among Recent UK Launches In April

Ivabradine stood out among recently-launched UK generics with an average price rise of more than a third in April, according to the latest figures from market researcher WaveData.

Market Intelligence Pricing Strategies

Perindopril And Pramipexole Prices Peak In March

Two products featured highly among the fastest-rising UK generics prices in March, but for different reasons.

Market Intelligence Generic Drugs

Wholesaler Hike Drives UK Price Spike In February

Increases by one particular wholesaler led to steep rises for a number of UK generics in February, according to market researcher WaveData.

Market Intelligence Generic Drugs

UK Penicillin Prices Spike In January

Our Pricewatch UK feature has seen a first with WaveData’s figures for January 2023, as all nine of our top Biggest Risers belonged to the same group of medicines, penicillins.

Market Intelligence Pricing Strategies
See All
UsernamePublicRestriction

Register